9EH Stock Overview Through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Evolent Health, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Evolent Health Historical stock prices Current Share Price US$10.80 52 Week High US$31.80 52 Week Low US$10.30 Beta 1.43 1 Month Change -14.29% 3 Month Change -58.14% 1 Year Change -64.24% 3 Year Change -54.62% 5 Year Change 33.33% Change since IPO -35.76%
Recent News & Updates
Evolent Health, Inc. Announces Executive Changes Dec 19
Third quarter 2024 earnings released: US$0.27 loss per share (vs US$0.30 loss in 3Q 2023) Nov 08
Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 and Reiterates Earnings Guidance for the Full Year 2024 Nov 08
Second quarter 2024 earnings released: EPS: US$0.014 (vs US$0.37 loss in 2Q 2023) Aug 09
Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2024 and for the Full Year Ending December 31, 2024 Aug 09
Evolent Health, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12 See more updates
Evolent Health, Inc. Announces Executive Changes Dec 19
Third quarter 2024 earnings released: US$0.27 loss per share (vs US$0.30 loss in 3Q 2023) Nov 08
Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 and Reiterates Earnings Guidance for the Full Year 2024 Nov 08
Second quarter 2024 earnings released: EPS: US$0.014 (vs US$0.37 loss in 2Q 2023) Aug 09
Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2024 and for the Full Year Ending December 31, 2024 Aug 09
Evolent Health, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
Evolent Health, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Raises Earnings Guidance for the Full Year Full Year Ending December 31, 2024 May 11
First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 1Q 2023) May 10
Evolent Health, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 20
Full year 2023 earnings released: US$1.28 loss per share (vs US$0.20 loss in FY 2022) Feb 23
Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024 Feb 23 Evolent Health, Inc., Annual General Meeting, Jun 06, 2024
Evolent Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Jan 26
Forecast to breakeven in 2024 Nov 16
Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2023 and Full Year 2023 Nov 03
Third quarter 2023 earnings released: US$0.30 loss per share (vs US$0.022 profit in 3Q 2022) Nov 03
Evolent Health, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 11
New minor risk - Insider selling Aug 18
Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.046 loss in 2Q 2022) Aug 03
Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023 and Reiterates Earnings Guidance for the Full Year Ending December 31, 2023 Aug 03
High number of new directors Aug 01 Evolent Health, Inc. Appoints Toyin Ajayi to Its Board of Directors Jul 27
Evolent Health, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 14 Evolent Health, Inc. Announces Executive Changes
Forecast breakeven date pushed back to 2024 May 04
Full year 2022 earnings released: US$0.20 loss per share (vs US$0.35 loss in FY 2021) Feb 24
Evolent Health, Inc., Annual General Meeting, Jun 08, 2023 Feb 16
Evolent Health, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Feb 01
Evolent Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Nov 18
High number of new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.022 (vs US$0.15 loss in 3Q 2021) Nov 04
Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 04
Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 03
Evolent Health, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 15
Saxena White P.A. Announces Proposed Settlement in Evolent Health, Inc. Securities Litigation Sep 20
Evolent Health, Inc. Announces Executive Changes Sep 07
Lead Independent Director recently sold €113k worth of stock Sep 03
High number of new directors Aug 25
Chief Financial Officer recently sold €618k worth of stock Aug 19
Second quarter 2022 earnings released: US$0.046 loss per share (vs US$0.11 loss in 2Q 2021) Aug 03 Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022
First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.13 loss in 1Q 2021) May 06
Evolent Health, Inc. Provides Unaudited Earnings Guidance for the Second Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022 May 05
Evolent Health, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 19
Evolent Health, Inc. Announces Changes to Board of Directors, Adds Michael Mentesana and Elevates Frank Williams to Chairman Role Apr 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Forecast breakeven date pushed back to 2024 Feb 25
Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2022 and Full Year Ending December 31, 2022 Feb 24
Evolent Health, Inc., Annual General Meeting, Jun 09, 2022 Feb 12
High number of new directors Nov 11
Forecast to breakeven in 2023 Nov 09
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.44 loss in 3Q 2020) Nov 04
Evolent Health, Inc. (NYSE:EVH) entered into a definitive agreement to acquire Vital Decisions, LLC from Windrose Health Investors III, L.P., fund managed by WindRose Health Investors, LLC for $130 million. Aug 06
Second quarter 2021 earnings released: US$0.11 loss per share (vs US$2.39 loss in 2Q 2020) Aug 05
First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.93 loss in 1Q 2020) May 07
Evolent Health, Inc. Provides Revenue Guidance for the Second Quarter and Full Year of Fiscal Year Ending December 31, 2021 May 06
Full year 2020 earnings released: US$3.94 loss per share (vs US$3.67 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27
New 90-day high: €16.90 Feb 26
Evolent Health, Inc., Annual General Meeting, Jun 10, 2021 Feb 13
Evolent Health, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 12
New 90-day high: €15.40 Jan 26
Evolent Health, Inc. Announces Executive Appointments Jan 14
New 90-day high: €13.90 Jan 08
Evolent Health, Inc. Appoints Craig Barbarosh to Board of Directors as A Class III Director and to the Strategy Committee and Compensation Committee Dec 23
New 90-day high: €12.80 Dec 19
New 90-day high: €12.20 Nov 24
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.44 loss per share Nov 07
Evolent Health's Subsidiary New Century Health to Support Florida Blue Medicare with Comprehensive Oncology Management Services Nov 06
New 90-day low: €8.80 Oct 29
New 90-day high - €11.90 Sep 02 Evolent Health, Inc. announced that it expects to receive $32.8 million in funding Aug 15
Shareholder Returns 9EH DE Healthcare Services DE Market 7D 0.9% -0.7% 0.5% 1Y -64.2% -21.5% 7.2%
See full shareholder returns
Return vs Market: 9EH underperformed the German Market which returned 7% over the past year.
Price Volatility Is 9EH's price volatile compared to industry and market? 9EH volatility 9EH Average Weekly Movement 14.0% Healthcare Services Industry Average Movement 6.2% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 9EH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9EH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Show more Evolent Health, Inc. Fundamentals Summary How do Evolent Health's earnings and revenue compare to its market cap? 9EH fundamental statistics Market cap €1.25b Earnings (TTM ) -€99.97m Revenue (TTM ) €2.36b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9EH income statement (TTM ) Revenue US$2.46b Cost of Revenue US$2.07b Gross Profit US$393.27m Other Expenses US$497.50m Earnings -US$104.23m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.91 Gross Margin 15.96% Net Profit Margin -4.23% Debt/Equity Ratio 48.9%
How did 9EH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 20:16 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Evolent Health, Inc. is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Gillmor Baird David Larsen BTIG Richard Close Canaccord Genuity
Show 20 more analysts 
